FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979654704> ?p ?o ?g. }

• W2979654704 abstract "Background Catamenial epilepsy describes a worsening of seizures in relation to the menstrual cycle and may affect around 40% of women with epilepsy. Vulnerable days of the menstrual cycle for seizures are perimenstrually (C1 pattern), at ovulation (C2 pattern), and during the luteal phase (C3 pattern). A reduction in progesterone levels premenstrually and reduced secretion during the luteal phase is implicated in catamenial C1 and C3 patterns. A reduction in progesterone has been demonstrated to reduce sensitivity to the inhibitory neurotransmitter in preclinical studies, hence increasing risk of seizures. A pre‐ovulatory surge in oestrogen has been implicated in the C2 pattern of seizure exacerbation, although the exact mechanism by which this surge increases risk is uncertain. Current treatment practices include the use of pulsed hormonal (e.g. progesterone) and non‐hormonal treatments (e.g. clobazam or acetazolamide) in women with regular menses, and complete cessation of menstruation using synthetic hormones (e.g. medroxyprogesterone (Depo‐Provera) or gonadotropin‐releasing hormone (GnRH) analogues (triptorelin and goserelin)) in women with irregular menses. Catamenial epilepsy and seizure exacerbation is common in women with epilepsy, and may have a significant negative impact on quality of life. Women may not be receiving appropriate treatment for their seizures because of uncertainty regarding which treatment works best and when in the menstrual cycle treatment should be taken, as well as the possible impact on fertility, the menstrual cycle, bone health, and cardiovascular health. This review aimed to address these issues in order to inform clinical practice and future research. Objectives To evaluate the efficacy and tolerability of hormonal and non‐hormonal treatments for seizures exacerbated by the menstrual cycle in women with regular or irregular menses. We synthesised the evidence from randomised controlled trials of hormonal and non‐hormonal treatments in women with catamenial epilepsy of any pattern. Search methods We searched the following databases to 10 January 2019: Cochrane Register of Studies (CRS Web; includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL)), MEDLINE (Ovid: 1946 to 9 January 2019), ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We used no language restrictions. We checked the reference lists of retrieved studies for additional reports of relevant studies. Selection criteria We included randomised and quasi‐randomised controlled trials (RCTs) of blinded or opeṉlabel design that randomised participants individually (i.e. cluster‐randomised trials were excluded). We included cross‐over trials if each treatment period was at least 12 weeks in length and the trial had a suitable wash‐out period. Types of interventions included: women with any pattern of catamenial epilepsy who received a hormonal or non‐hormonal drug intervention in addition to an existing antiepileptic drug regimen for a minimum treatment duration of 12 weeks. Data collection and analysis We extracted data on study design factors and participant demographics for the included studies. The primary outcomes of interest were: proportion seizure‐free, proportion of responders (at least 50% decrease in seizure frequency from baseline), and mean change in seizure frequency. Secondary outcomes included: number of withdrawals, number of women experiencing adverse events of interest (seizure exacerbation, cardiac events, thromboembolic events, osteoporosis and bone health, mood disorders, sedation, menstrual cycle disorders, and fertility issues), and quality of life outcomes. Main results We identified 62 records from the databases and search strategies. Following title, abstract, and full‐text screening, we included eight full‐text articles reporting on four double‐blind, placebo‐controlled RCTs. We included two cross‐over RCTs of pulsed norethisterone and two parallel RCTs of pulsed progesterone recruiting a total of 192 women aged between 13 and 45 years with catamenial epilepsy. We found no RCTs for non‐hormonal treatments of catamenial epilepsy or for women with irregular menses. Meta‐analysis was not possible for the primary outcomes, therefore we undertook a narrative synthesis. For the two RCTs evaluating norethisterone versus placebo (24 participants), there were no reported treatment differences for mean change in seizure frequency. Outcomes for the proportion seizure‐free and 50% responders were not reported. For the RCTs evaluating progesterone versus placebo (168 participants), the studies reported conflicting results on the primary outcomes. One progesterone RCT reported no significant difference between progesterone 600 mg/day taken on day 14 to 28 and placebo with respect to 50% responders, seizure freedom rates, and change in seizure frequency for any seizure type. The other progesterone RCT reported that the decrease in seizure frequency from baseline in the progesterone group was significantly higher than the decrease in seizure frequency from baseline in the placebo group. Results of secondary efficacy outcomes showed no significant difference in terms of treatment withdrawal for any reason in the pooled progesterone RCTs when compared to placebo (pooled risk ratio (RR) 1.56, 95% confidence interval (CI) 0.81 to 3.00, P = 0.18, I2 = 0%) or for treatment withdrawals due to adverse events (pooled RR 2.91, 95% CI 0.53 to 16.17, P = 0.22, I2 = 0%). No treatment withdrawals from the norethisterone RCTs were reported. The RCTs reported limited information on adverse events, although one progesterone RCT reported no significant difference in the number of women experiencing adverse events (diarrhoea, dyspepsia, nausea, vomiting, fatigue, nasopharyngitis, dizziness, headache, and depression). No studies reported on quality of life. We judged the evidence from the included progesterone RCTs to be of low to moderate certainty due to risk of bias and from the included norethisterone RCTs to be of very low certainty due to serious imprecision and risk of bias. Authors' conclusions This review provides very low‐certainty evidence of no treatment difference between norethisterone and placebo, and moderate‐ to low‐certainty evidence of no treatment difference between progesterone and placebo for catamenial epilepsy. However, as all the included studies were underpowered, important clinical effects cannot be ruled out. Our review highlighted an overall deficiency in the literature base on the effectiveness of a wide range of other hormonal and non‐hormonal interventions currently being used in practice, particularly for those patients who do not have regular menses. Further clinical trials are needed in this area." @default.
• W2979654704 created "2019-10-18" @default.
• W2979654704 creator A5017559586 @default.
• W2979654704 creator A5089343835 @default.
• W2979654704 date "2019-10-14" @default.
• W2979654704 modified "2023-09-25" @default.
• W2979654704 title "Treatments for seizures in catamenial (menstrual-related) epilepsy" @default.
• W2979654704 cites W1247968195 @default.
• W2979654704 cites W15119525 @default.
• W2979654704 cites W1551781691 @default.
• W2979654704 cites W161562191 @default.
• W2979654704 cites W1932154717 @default.
• W2979654704 cites W195924149 @default.
• W2979654704 cites W1969836710 @default.
• W2979654704 cites W1970989600 @default.
• W2979654704 cites W1987034237 @default.
• W2979654704 cites W1999336422 @default.
• W2979654704 cites W2007884033 @default.
• W2979654704 cites W2013722076 @default.
• W2979654704 cites W2022764608 @default.
• W2979654704 cites W2027351733 @default.
• W2979654704 cites W2046566032 @default.
• W2979654704 cites W2049710739 @default.
• W2979654704 cites W2056154551 @default.
• W2979654704 cites W2059542358 @default.
• W2979654704 cites W2061549777 @default.
• W2979654704 cites W2064543052 @default.
• W2979654704 cites W2067638295 @default.
• W2979654704 cites W2091306609 @default.
• W2979654704 cites W2091757374 @default.
• W2979654704 cites W2095512836 @default.
• W2979654704 cites W2103024352 @default.
• W2979654704 cites W2112264559 @default.
• W2979654704 cites W2121403142 @default.
• W2979654704 cites W2121587872 @default.
• W2979654704 cites W2127146014 @default.
• W2979654704 cites W2130235475 @default.
• W2979654704 cites W2142169831 @default.
• W2979654704 cites W2145341481 @default.
• W2979654704 cites W2156098321 @default.
• W2979654704 cites W2589648781 @default.
• W2979654704 cites W2904873708 @default.
• W2979654704 cites W2991792334 @default.
• W2979654704 cites W4233635697 @default.
• W2979654704 doi "https://doi.org/10.1002/14651858.cd013225.pub2" @default.
• W2979654704 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8444032" @default.
• W2979654704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34528245" @default.
• W2979654704 hasPublicationYear "2019" @default.
• W2979654704 type Work @default.
• W2979654704 sameAs 2979654704 @default.
• W2979654704 citedByCount "12" @default.
• W2979654704 countsByYear W29796547042020 @default.
• W2979654704 countsByYear W29796547042021 @default.
• W2979654704 countsByYear W29796547042022 @default.
• W2979654704 countsByYear W29796547042023 @default.
• W2979654704 crossrefType "journal-article" @default.
• W2979654704 hasAuthorship W2979654704A5017559586 @default.
• W2979654704 hasAuthorship W2979654704A5089343835 @default.
• W2979654704 hasBestOaLocation W29796547042 @default.
• W2979654704 hasConcept C118552586 @default.
• W2979654704 hasConcept C126322002 @default.
• W2979654704 hasConcept C134018914 @default.
• W2979654704 hasConcept C143228043 @default.
• W2979654704 hasConcept C2777014857 @default.
• W2979654704 hasConcept C2777702977 @default.
• W2979654704 hasConcept C2778186239 @default.
• W2979654704 hasConcept C2778575703 @default.
• W2979654704 hasConcept C2778894405 @default.
• W2979654704 hasConcept C2779058012 @default.
• W2979654704 hasConcept C2779771394 @default.
• W2979654704 hasConcept C42407357 @default.
• W2979654704 hasConcept C71315377 @default.
• W2979654704 hasConcept C71924100 @default.
• W2979654704 hasConceptScore W2979654704C118552586 @default.
• W2979654704 hasConceptScore W2979654704C126322002 @default.
• W2979654704 hasConceptScore W2979654704C134018914 @default.
• W2979654704 hasConceptScore W2979654704C143228043 @default.
• W2979654704 hasConceptScore W2979654704C2777014857 @default.
• W2979654704 hasConceptScore W2979654704C2777702977 @default.
• W2979654704 hasConceptScore W2979654704C2778186239 @default.
• W2979654704 hasConceptScore W2979654704C2778575703 @default.
• W2979654704 hasConceptScore W2979654704C2778894405 @default.
• W2979654704 hasConceptScore W2979654704C2779058012 @default.
• W2979654704 hasConceptScore W2979654704C2779771394 @default.
• W2979654704 hasConceptScore W2979654704C42407357 @default.
• W2979654704 hasConceptScore W2979654704C71315377 @default.
• W2979654704 hasConceptScore W2979654704C71924100 @default.
• W2979654704 hasLocation W29796547041 @default.
• W2979654704 hasLocation W29796547042 @default.
• W2979654704 hasLocation W29796547043 @default.
• W2979654704 hasOpenAccess W2979654704 @default.
• W2979654704 hasPrimaryLocation W29796547041 @default.
• W2979654704 hasRelatedWork W1923012151 @default.
• W2979654704 hasRelatedWork W2013607481 @default.
• W2979654704 hasRelatedWork W2110302576 @default.
• W2979654704 hasRelatedWork W2156873448 @default.
• W2979654704 hasRelatedWork W2989894845 @default.
• W2979654704 hasRelatedWork W3097548851 @default.
• W2979654704 hasRelatedWork W3120125528 @default.
• W2979654704 hasRelatedWork W3192227330 @default.

• next